These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 1731899)

  • 1. A region of tissue plasminogen activator that affects plasminogen activation differentially with various fibrin(ogen)-related stimulators.
    Eastman D; Wurm FM; van Reis R; Higgins DL
    Biochemistry; 1992 Jan; 31(2):419-22. PubMed ID: 1731899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of the mechanism responsible for the increased fibrin specificity of TNK-tissue plasminogen activator relative to tissue plasminogen activator.
    Stewart RJ; Fredenburgh JC; Leslie BA; Keyt BA; Rischke JA; Weitz JI
    J Biol Chem; 2000 Apr; 275(14):10112-20. PubMed ID: 10744692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Involvement of residues 296-299 in the enzymatic activity of tissue-type plasminogen activator.
    Paoni NF; Refino CJ; Brady K; Peña LC; Nguyen HV; Kerr EM; Johnson AC; Wurm FM; van Reis R; Botstein D
    Protein Eng; 1992 Apr; 5(3):259-66. PubMed ID: 1409547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of the one-chain to two-chain conversion in tissue plasminogen activator: characterization of mutations at position 275.
    Higgins DL; Lamb MC; Young SL; Powers DB; Anderson S
    Thromb Res; 1990 Feb; 57(4):527-39. PubMed ID: 2139248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of kinetic parameters of the activation of Glu-plasminogen by tissue plasminogen activator obtained from various sources.
    Takada A; Sugawara Y; Takada Y
    Haemostasis; 1988; 18(2):117-25. PubMed ID: 3137140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A variant of t-PA (T103N, KHRR 296-299 AAAA) that, by bolus, has increased potency and decreased systemic activation of plasminogen.
    Refino CJ; Paoni NF; Keyt BA; Pater CS; Badillo JM; Wurm FM; Ogez J; Bennett WF
    Thromb Haemost; 1993 Aug; 70(2):313-9. PubMed ID: 8236141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the effects of fibrinogen and fibrin products and isolated peptide chains on the fibrin-mediated stimulation of plasminogen activation by tissue-type plasminogen activator, and on the fibrin-dependent enhancement of the amidolytic activity of one-chain tissue-type plasminogen activator.
    Fischer B
    Biol Chem Hoppe Seyler; 1990 Nov; 371(11):1067-75. PubMed ID: 2128181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparative study of the promotion of tissue plasminogen activator and pro-urokinase-induced plasminogen activation by fragments D and E-2 of fibrin.
    Liu JN; Gurewich V
    J Clin Invest; 1991 Dec; 88(6):2012-7. PubMed ID: 1836471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soluble fibrin degradation products potentiate tissue plasminogen activator-induced fibrinogen proteolysis.
    Weitz JI; Leslie B; Ginsberg J
    J Clin Invest; 1991 Mar; 87(3):1082-90. PubMed ID: 1900308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of intact fibrin and partially plasmin-degraded fibrin on kinetic properties of one-chain tissue-type plasminogen activator.
    Fischer BE; Will H
    Biochim Biophys Acta; 1990 Oct; 1041(1):48-54. PubMed ID: 2145980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparative study of amyloid-beta (1-42) as a cofactor for plasminogen activation by vampire bat plasminogen activator and recombinant human tissue-type plasminogen activator.
    Kruithof EK; Schleuning WD
    Thromb Haemost; 2004 Sep; 92(3):559-67. PubMed ID: 15351852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of fibrin-like stimulators on the activation of plasminogen by tissue-type plasminogen activator (t-PA)--studies with active site mutagenized plasminogen and plasmin resistant t-PA.
    Lijnen HR; Van Hoef B; De Cock F; Collen D
    Thromb Haemost; 1990 Aug; 64(1):61-8. PubMed ID: 2148848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble, cross-linked fibrin(ogen) hybrid oligomers do not stimulate t-PA conversion of plasminogen.
    Grøn B; Bennick A; Filion-Myklebust C; Matsueda GR; Nieuwenhuizen W; Brosstad F
    Thromb Res; 1992 May; 66(2-3):231-8. PubMed ID: 1412194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of various structural domains of fibrinogen and fibrin on the potentiation of plasminogen activation by recombinant tissue plasminogen activator.
    de Serrano VS; Urano T; Gaffney PJ; Castellino FJ
    J Protein Chem; 1989 Feb; 8(1):61-77. PubMed ID: 2527513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design of a novel chimeric tissue plasminogen activator with favorable Vampire bat plasminogen activator properties.
    Kazemali M; Majidzadeh-A K; Sardari S; Saadatirad AH; Khalaj V; Zarei N; Barkhordari F; Adeli A; Mahboudi F
    Enzyme Microb Technol; 2014 Dec; 67():82-6. PubMed ID: 25442953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluorogenic fibrinogen and fibrin facilitate macromolecular assembly and dynamic assay of picomolar levels of plasminogen activators under well mixed conditions.
    Wu JH; Diamond SL
    Thromb Haemost; 1995 Aug; 74(2):711-7. PubMed ID: 8585011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinetic analysis of covalent hybrid plasminogen activators: effect of CNBr-degraded fibrinogen on kinetic parameters of Glu1-plasminogen activation.
    Lee PP; Wohl RC; Boreisha IG; Robbins KC
    Biochemistry; 1988 Sep; 27(19):7506-13. PubMed ID: 2974723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. On the molecular interactions between fibrin, tissue-type plasminogen activator and plasminogen.
    Lijnen HR; Van Hoef B; Collen D
    Thromb Res Suppl; 1990; 10():45-54. PubMed ID: 2107598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences between neonates and adults in tissue-type-plasminogen activator (t-PA)-catalyzed plasminogen activation with various effectors and in carbohydrate sequences of fibrinogen chains.
    Ries M; Easton RL; Longstaff C; Zenker M; Corran PH; Morris HR; Dell A; Gaffney PJ
    Thromb Res; 2001 Aug; 103(3):173-84. PubMed ID: 11672579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biochemical, thrombolytic and pharmacokinetic properties of rt-PA P47G, K49N, a substitution variant of human tissue-type plasminogen activator.
    Nelles L; Li XK; Vanlinthout I; De Cock F; Lijnen HR; Collen D
    Thromb Haemost; 1992 Apr; 67(4):445-52. PubMed ID: 1631793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.